Dear Luke,
I’m embarrassed by the untimely response to your post. I first saw your post a couple of weeks ago when our digital marketing person came across it. Due to the extensive nature of your post I set it aside to a time when I could devote the time such a post deserves. You bring up some great questions and I appreciate you giving us a chance to respond.
First off, not all warming devices are the same and
there are no similar devices. Our FDA-cleared and patented device and process (3 U.S. and 8 International patents) uses negative pressure to expand and keep the Arteriovenous Anastomosis vascular bed in the palm of the hand (our portal into the circulatory system) vasodilated so as we simultaneously apply heat to this pool of blood, this allows us to continue to slowly and safely raise core body temperature to the point where the peripheral capillaries dilate to radiate this excess heat. The net effect of this complex process is to warm the body from the inside out therefore increasing muscular relaxation throughout the body. The application of negative pressure and heat is clinically proven to be more effective than heat alone (Grahn et al 1998). Link:
http://journals.lww.com/anesthesia-...volution_of_A_Technique_for_Treating.204.aspx
Our device has over 3,000 firmware instructions to manage this process safely. Those “goofy” devices you recommend, can seriously damage the skin because they apply heat externally (LOL, I thought I was the only one who used “goofy” when describing such treatment modalities). Because they can only treat a localized area, after a few minutes their external application of heat causes the underlying capillaries to vasoconstrict in order to maintain core body temperature at normothermia. From that point forward the “goofy” devices simply cook the skin. The AVACEN 100 utilizes a much more subtle heat technology platform that allows the body to naturally and safely handle this heat infusion, which prevents the body from dangerously overheating, which could happen with saunas.
Concerning your question regarding a dysfunctional circulatory system; it is estimated that 80% of the population over 40 have compromised microcirculation. We believe our wide range of effectiveness for many different maladies points to our effect on increasing whole body microcirculation. In addition, a more gradual heat infusion platform is a much safer option for any systemic dysfunction.
As for throwing our study into the “junk” category; I am not sure why you said that but I respect your skepticism. It is not easy to have a control group when subjects can sense if the heat is being applied. In a perfect world, a double-blind placebo-controlled randomized study would have been ideal (wish we had the deep pockets of big pharma…).
Given the fact that heat or no heat is almost impossible to blind, we compared Group A’s 10-minute once a day sub-therapeutic dose against Group B’s therapeutic dose of 15-minutes twice a day. The results were extremely convincing.
Yes, our study had a low number of subjects but we had exceptional results. Even the FDA accepts that a high result with a low number of subjects can be equivalent to a large number of subjects with minimal results. Just take a look at the FDA approved drugs for fibromyalgia. They all had minimal clinical results but they were from a large population.
I am very proud of our study and results:
https://clinicaltrials.gov/ct2/show/NCT01619579?term=avacen&rank=1
Currently there is a manuscript being completed which should be peer reviewed and published with the next 12 months.
When judging the quality of our trial I think it would be fair to:
- Examine the University of California San Diego and Department of Veteran Affairs IRB approved 15 page research plan which has numerous scientifically recognized controls.
- Review the credentials of the 5 amazing MD’s and researchers who conducted the study.
- Evaluate the 10 endpoints that were studied and reported on.
- Understand that the trial consisted of 56 separate treatments over 28 days for each subject.
- Take a look at the Board of Directors (https://avacen.com/team/board-members/) of the company (AVACEN) who sponsored the trial which includes the innovator of Savella.
Just so you know… you’re not in a unique club with your opinions. Such opinions are not unusual when a new, innovative and disruptive medical device is presented to the scientific community. Most Western doctors need a “stamp of approval” such as a peer reviewed and published study before they begin to use a product such as ours.
I personally believe it is just as important to understand the validity of the mechanism of action and then ask yourself… does that make sense?
Our priority as a company has always been to demonstrate efficacy and safety while simultaneously exploring the mechanism of action of our technology. Many of our physicians and patients feel our clinical data is sufficient to at the very least try our non-invasive technology which has been cleared as safe by the FDA for over-the-counter (OTC) sales. Others want to better understand why and how our device is effective. As I mentioned above, there also is a portion of the community that will not believe anything until it is published in a peer-reviewed journal. I find this interesting because people have been taking aspirin, ibuprofen, and other OTC medications for decades without reading their clinical studies or safety profile.
As a small company with a disruptive medical device, I am extremely proud of the progress we have made thus far, but we realize our clinical credibility can always be improved. But, there comes a time when development cost and product launch date has to supersede the demands of those who desire years of million dollar studies comprised of hundreds of subjects in multiple geographic areas. The costs associated with the foregoing data collection and analysis must be minimized if an affordable effective consumer product under $3,000 is the desired result. This is especially true with a noninvasive and safe device (ZERO negative reports for 100% of over the 500,000 treatments).
Your comment that our study was done for marketing purposes is 100% correct. I really can’t think of one medical device (or drug) study that was done for any other purpose. Even the National Institutes of Health require, in their research grant application, that you prove there is a path to commercialization.
And finally (I know you thought my response would never end) you’re Caveat Emptor recommendation is not necessary when buying our product.
We have come to understand that everyone’s medical history and condition is different… therefore, we don’t wish to inflict any additional stress into our customer’s life by having them pay for something that doesn’t work. Thus, we have recently changed our trial policy. If used as recommended, and if it doesn’t help, we guarantee a 100% return of all monies paid to purchase our device - including shipping costs both ways! Details:
www.avacen.com
Thanks again for you interest and wishing you good health, TOM